II. Background
- No longer available (off market in U.S.) due to hepatotoxicity
- Listed for historical reasons only
III. Mechanism
IV. Indications: Non-Valvular Atrial Fibrillation
- Warfarin intolerant
- Patients with high risk of Intracranial Hemorrhage
V. Efficacy
- Advantages
- As effective as Warfarin with INR 2-3
- Ximelagartan does not require monitoring
- Ximelagartan has fewer bleeding complications
- Disadvantages
- Expensive
- Myocardial Ischemia risk
- Risk of severe liver toxicity
VI. Dosing
- Studies used fixed dose of 36 mg bid
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
MSH | C426686 |
SnomedCT | 415853004 |
English | xi-melagatran, XIMELAGATRAN, ximelagatran [Chemical/Ingredient], Ximelagatran (substance), Ximelagratan, Ximelagratan (substance), Ximelagatran, glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, ximelagatran |
Spanish | ximelagatrán, ximelagatrán (sustancia), ximelagratan, ximelagratan (sustancia) |